PharVision Advisers, LLC
•CIK: 1898824•Filing: Q4 2025
**PharVision Advisers, LLC** manages $198M across a diversified portfolio of 667 positions. The fund exhibits concentrated exposure to key technology and healthcare names, with top holdings including EXLS, DK, STT-PG, ASAN, and AVGO, each representing significant allocations around the $0.7M mark. Notable positions also include NVDA and ITRI, indicating a strategic focus on high-growth, sector-specific opportunities. This structure suggests a tactical, research-driven approach within the life sciences and technology verticals.
Total AUM
$197.5M
QoQ Performance
+11.1%
Positions
664
Top 10 Concentration
7.7%
Latest Filing
Q4 2025
Top Holdings Allocation
EXLS0.4%
DK0.4%
FVRR0.4%
ASAN0.3%
AVGO0.3%
ITRI0.3%
EAT0.3%
HLF0.3%
📈 Biggest Buys
📉 Biggest Sells
Sector Breakdown
Other93.9%
Consumer2.3%
Technology1.5%
Healthcare0.9%
Communication0.9%
Energy0.5%
🚪 Exited Positionssold since Q3 2025
+565 more exited positions
Changes from Q3 2025
NEW116 new positions
↑67 increased
↓17 decreased
Historical Filings
Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024